SL
SUPN icon

Salomon & Ludwin’s Supernus Pharmaceuticals SUPN Stock Holding History

Salomon & Ludwin’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.1K Buy
755
+257
+52% +$13.1K ﹤0.01% 643
2025
Q4 		$24.6K Buy
498
+95
+24% +$4.62K ﹤0.01% 740
2025
Q3 		$19.5K Buy
+403
New +$16.2K ﹤0.01% 830

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Salomon & Ludwin's SUPN Position: Q1 2026 in Review

Salomon & Ludwin increased its Supernus Pharmaceuticals (SUPN) stake by 52% in Q1 2026, buying an estimated $13.1K and bringing the position to 755 shares worth $38.1K. The position accounts for ﹤0.01% of the portfolio, ranked #643.

Salomon & Ludwin first reported a position in SUPN in Q3 2025 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Salomon & Ludwin held 755 shares of Supernus Pharmaceuticals worth $38.1K as of Q1 2026.
  • Salomon & Ludwin bought 257 Supernus Pharmaceuticals shares in Q1 2026, an estimated $13.1K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #643 holding.
  • Salomon & Ludwin first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.